DERM

Journey Medical is a commercial-stage dermatology marketer (eight FDA-approved products) whose fundamentals are improving off a low base but remain unproven. FY2025 revenue of $61.2M grew 11.1%, yet the five-year record is choppy and net flat — $63.1M (2021) → $71.0M (2022) → $59.7M (2023) → $55.1M (2024) → $61.2M (2025) — so this is not a durable-growth story, it's a portfolio being defended against erosion. The MD&A confirms the risk: Accutane already competes against five AB-rated generics and Targadox faces generic competition, while only Qbrexza, Amzeeq, Zilxi and the newly approved Emrosi carry patent protection. R&D was gutted 95% to $480K, so there is essentially no internal pipeline — future growth rides entirely on commercializing acquired/licensed products.

The trajectory is the constructive part. Operating loss narrowed 40% to -$8.17M, net loss improved 22% to -$11.4M, and equity rose 59% to $31.9M. But the company still burns cash: operating cash flow was -$12.4M against $24.1M of cash, implying roughly two years of runway before a raise, and shares already grew ~20% year-over-year — dilution is the funding mechanism. Leverage is meaningful at 1.97x liabilities/equity with $25.3M of long-term debt, and the -$98.5M accumulated deficit underscores that this business has never generated cumulative profit. ROE of -35.9% reflects losses on a thin equity base.